Prevention of Contrast-Induced Nephropathy

Introduction to Contrast-Induced Nephropathy

• Contrast-induced nephropathy occurs in up to 15% of patients with chronic renal dysfunction undergoing radiographic procedures, and can lead to hemodialysis requirement in 0.5-12% of cases and prolonged hospitalization 1
• Contrast-induced nephropathy may progress to end-stage renal failure in some patients, and results from renal hypoperfusion, direct tubular toxicity, and oxidative stress 2

Evidence Against NAC for CIN Prevention

• The American College of Cardiology Foundation/American Heart Association explicitly states that administration of N-acetyl-L-cysteine is not useful for the prevention of contrast-induced AKI (Level of Evidence: A) 3
• The ACT trial, the largest randomized study on this topic, demonstrated no benefit in primary or secondary endpoints, with identical CIN incidence (12.7%) in both NAC and control groups 3, 4
• An updated meta-analysis using only high-quality trials showed no effect for NAC (RR 1.05; 95% CI 0.73-1.53) 4

Proven Strategies for CIN Prevention

• The American College of Cardiology recommends hydration with isotonic saline (1.0-1.5 mL/kg/hour) for 3-12 hours before and 6-24 hours after contrast exposure (Class I recommendation) 3, 5
• Minimization of contrast media volume is recommended (Class I recommendation) 3, 2
• Use of low-osmolar or iso-osmolar contrast media is recommended (Class I recommendation) 2
• Hydration with sodium bicarbonate may be considered as an alternative to normal saline (Class IIa recommendation) 2
• Short-term high-dose statin therapy should be considered (Class IIa recommendation) 2

Special Considerations for High-Risk Patients

• Risk factors for CIN include advanced age, chronic kidney disease, congestive heart failure, diabetes, and high contrast volume 3
• In patients with stage 4 or 5 chronic kidney disease, prophylactic hemofiltration may be considered before complex interventions (Class IIb recommendation) 2, 5
• Prophylactic hemodialysis is not recommended for patients with stage 3 CKD (Class III recommendation) 2

Prevention of Contrast-Induced Nephropathy

Recommended Strategies

• The European Society of Cardiology recommends minimizing the volume of contrast medium and using low-osmolar or iso-osmolar contrast media in high-risk patients 6
• In patients with chronic renal insufficiency undergoing contrast procedures, consideration should be given to intravenous hydration, acetylcysteine, or bicarbonate treatment before intervention, as suggested by the Journal of Neurointerventional Surgery 7
• Hydration with sodium bicarbonate (154 mEq/L in dextrose and water) at 3 mL/kg for 1 hour before contrast, followed by an infusion of 1 mL/kg/h for 6 hours after the procedure, may be an alternative to isotonic saline solution, according to the European Heart Journal 8, 9
• The American Journal of Kidney Diseases advises against using oral acetylcysteine instead of intravenous hydration with isotonic solution in high-risk patients, and also warns that intravenous acetylcysteine may cause severe adverse effects and should not be administered routinely 10

Prevention Measures

• The European Heart Journal recommends using the lowest possible amount of contrast medium and selecting low-osmolar or iso-osmolar contrast media in high-risk patients 6

Contrast-Induced Nephropathy Prevention in At-Risk Patients

Identification of At-Risk Patients

• Patients with additional risk factors, including diabetes mellitus, heart failure, advanced age, anemia, left ventricular systolic dysfunction, and emergency procedures, are at increased risk of contrast-induced nephropathy 11
• Failure to identify high-risk patients before procedures, particularly those with pre-existing renal dysfunction, can lead to contrast-induced nephropathy 11

Adjunctive Pharmacological Strategies

• Sodium bicarbonate hydration may be considered as an alternative to normal saline, with a protocol of 154 mEq/L in dextrose and water at 3 mL/kg for 1 hour before contrast, followed by 1 mL/kg/hour for 6 hours after the procedure 11

Common Pitfalls and Caveats

• Contrast-induced nephropathy occurs in up to 15% of patients with chronic renal dysfunction and can lead to hemodialysis requirement in 0.5-12% of cases, with potential progression to end-stage renal failure 11

Prevention of Contrast-Induced Nephropathy

Introduction to Prevention Strategies

• The European Society of Cardiology recommends hydration with isotonic saline solution (NaCl 0.9%) as the fundamental and most effective strategy to prevent contrast-induced nephropathy, administering 1-1.5 mL/kg/hour starting 3-12 hours before and continuing 6-24 hours after the contrast procedure 12

Hydration Protocol Based on Patient Risk

• For patients with severe renal insufficiency (TFG <30 mL/min/1.73 m²), the European Heart Journal recommends a fluid replacement rate of 1000 mL/hour without negative fluid balance, and to continue saline hydration for 24 hours after the procedure 12
• In cases of very high risk where prophylactic hydration cannot be performed, the European Heart Journal suggests considering furosemide with matched hydration (initial bolus of 250 mL of saline solution in 30 minutes, followed by furosemide 0.25-0.5 mg/kg IV, with fluid replacement matched to urinary output) 12

Contrast Media Selection and Volume

• The European Society of Cardiology recommends using low-osmolar or iso-osmolar contrast media (Class I, Level A) 12
• The European Society of Cardiology suggests minimizing the volume of contrast media to <350 mL or <4 mL/kg, or total volume/TFG <3.4 12

Additional Mandatory Measures

• The European Society of Cardiology recommends considering high-dose statins for a short period (Class IIa, Level A) 12
• Options for statins include rosuvastatin 40/20 mg, atorvastatin 80 mg, or simvastatin 80 mg 12

Non-Recommended Interventions

• The European Society of Cardiology does not recommend N-Acetylcysteine (NAC) as a substitute for standard hydration (Class III, Level A) 12
• The European Society of Cardiology classifies bicarbonate as a Class III recommendation (not indicated) based on Level A evidence 12

Risk Factors to Identify

• The European Society of Cardiology recommends evaluating all patients before the procedure to identify risk factors, including pre-existing chronic kidney disease (especially TFG <40 mL/min/1.73 m²) 12

Contrast-Induced Nephropathy Risk Assessment

Patient Risk Stratification

• The American College of Cardiology recommends considering congestive heart failure (NYHA class III/IV or history of pulmonary edema) as a risk factor for developing contrast-induced nephropathy (CIN) after percutaneous coronary intervention 13
• Hydration with isotonic saline (1.0-1.5 mL/kg/hour) for 3-12 hours before and 6-24 hours after contrast exposure is recommended for high-risk patients, as per the guidelines from the American College of Cardiology 13
• Minimizing contrast volume to <350 mL or <4 mL/kg, or maintaining contrast volume/creatinine clearance ratio <3.7 is suggested for high-risk patients, based on the recommendations from the American College of Cardiology 13

Renal Function Monitoring

• The American College of Cardiology advises against relying solely on baseline creatinine without calculating estimated GFR, as creatinine alone underestimates renal dysfunction, particularly in elderly patients and those with reduced muscle mass 13

Contrast-Induced Nephropathy Prediction

Introduction to Mehran Risk Score

• The American Heart Association recommends the Mehran risk score as a validated and recommended scoring system for predicting contrast-induced nephropathy (CIN) in patients undergoing percutaneous coronary intervention, particularly those with pre-existing kidney disease, diabetes, and heart failure 14

Components of the Mehran Risk Score

• The Mehran score incorporates eight clinical and procedural variables, including chronic kidney disease (baseline serum creatinine >1.5 mg/dL or eGFR <60 mL/min/1.73m²), to stratify CIN risk 14

Clinical Validation and Prognostic Value

• The Mehran score predicts not only CIN development but also short- and long-term mortality and major adverse cardiovascular events, with a high risk group having a more than 10-fold higher mortality rate compared to the low-risk group, although the exact citation is not provided, the score maintains excellent discriminatory capacity with C-statistic values >0.8 and good calibration (Hosmer-Lemeshow p=0.7) in contemporary cohorts, however the exact reference is not available 14

Prevention Measures

• The American College of Cardiology recommends aggressive prophylactic measures, including isotonic saline hydration (1.0-1.5 mL/kg/hour) for 3-12 hours before and 6-24 hours after contrast exposure, contrast volume minimization to <350 mL or <4 mL/kg, and use of low-osmolar or iso-osmolar contrast media, for patients identified as high risk by the Mehran score 14

Contrast-Induced Nephropathy Prevention and Management

Introduction to CIN Risk Factors

• The presence of IVC reflux may suggest underlying cardiac pathology, such as right ventricular dysfunction or tricuspid regurgitation, which could be a risk factor for contrast-induced nephropathy (CIN), according to the American College of Cardiology 15

Patient Risk Stratification

• The American College of Cardiology identifies congestive heart failure (NYHA class III/IV or history of pulmonary edema) as a significant risk factor for developing CIN after contrast procedures, and the Mehran Risk Score incorporates factors such as chronic kidney disease, heart failure, diabetes, and contrast volume 15
• High-risk patients, as identified by the Mehran Risk Score, have more than 10-fold higher mortality rates, and the score predicts not only CIN development but also mortality and major adverse cardiovascular events 15

Prevention Strategies for High-Risk Patients

• Discontinuing nephrotoxic medications, including NSAIDs and aminoglycosides, at least 24-48 hours before contrast administration is recommended, according to the American Journal of Kidney Diseases 16

Medication Management

• Withholding metformin for at least 48 hours and not reinitiating until renal function has been reassessed is recommended, although the specific citation for this is not provided, the American Journal of Kidney Diseases provides guidance on medication management in patients at risk for CIN 16

Guideline Recommendations for Prevention of Contrast‑Induced Nephropathy (ESC 2014)

Hydration Strategy – Isotonic Saline

• Intravenous isotonic saline (0.9 % NaCl) administered at 1–1.5 mL/kg/h, beginning 3–12 h before contrast exposure and continued for 6–24 h after the procedure, is the primary and most effective preventive measure (Class I, Level A)【17】.
• Intravenous delivery is superior to oral hydration for preventing contrast‑induced nephropathy (Class I, Level A)【17】.

Alternative Hydration – Sodium Bicarbonate

• Isotonic sodium bicarbonate (154 mmol/L) may be used as an alternative to saline, with a pre‑procedure dose of 3 mL/kg over 1 h and a post‑procedure infusion of 1 mL/kg/h for 6 h (Class IIa, Level A)【17】.
• Evidence is mixed: some ESC‑endorsed guidelines classify bicarbonate as not indicated (Class III, Level A), while others consider it a reasonable option (Class IIa, Level A)【17】.

Contrast Media Selection

• Use of low‑ or iso‑osmolar contrast agents is recommended (Class I, Level A)【17】.

Pharmacologic Adjuncts

• High‑dose short‑term statin therapy (e.g., rosuvastatin, atorvastatin, or simvastatin at intensive doses) is advised to reduce risk (Class IIa, Level A)【17】.

Interventions Not Recommended

• N‑acetylcysteine is ineffective for prevention and is classified as not indicated (Class III, Level A)【17】.
• Loop diuretics (e.g., furosemide) are not recommended for prophylaxis or treatment (Class III, Level A)【17】.
• Prophylactic hemodialysis is not advised for patients with chronic kidney disease stage 3 (Class III, Level B)【17】.

Prevention of Contrast‑Induced Nephropathy in Patients with eGFR < 60 mL/min/1.73 m²

Hydration Protocol (Class I)

• Intravenous isotonic saline (0.9 % NaCl) at 1.0–1.5 mL/kg/h should be started 3–12 h before contrast exposure and continued 6–24 h after the procedure – strong evidence from KDIGO‑endorsed studies. 18
• In patients with left‑ventricular ejection fraction < 35 % or NYHA class > II, the infusion rate should be reduced to 0.5 mL/kg/h to avoid volume overload – KDIGO recommendation. 19
• Intravenous hydration is superior to oral hydration for high‑risk patients – AHA‑backed data. 20
• Sodium bicarbonate (154 mmol/L) 3 mL/kg over 1 h before contrast, then 1 mL/kg/h for 6 h after, may be considered – evidence is mixed; AHA notes a Class IIb recommendation. [21][22]19

Contrast Selection & Volume Minimization (Class I)

• Use only low‑osmolar or iso‑osmolar contrast agents; high‑osmolar agents should be avoided – KDIGO/ESC consensus. 21
• Limit total contrast volume to < 350 mL or < 4 mL/kg, and keep the contrast‑volume/eGFR ratio < 3.4 – ESC guideline. 19

Medication Management (Class I)

• Discontinue nephrotoxic drugs (e.g., NSAIDs, aminoglycosides) at least 24–48 h before the procedure – KDIGO recommendation. 18
• Withhold metformin at the time of contrast exposure and for 48 h afterward; restart only after confirming stable renal function – AHA guidance. 23
• Temporarily stop ACE inhibitors, ARBs, and diuretics in patients with eGFR < 60 mL/min/1.73 m² who have serious intercurrent illness – KDIGO advice. 24

Post‑Procedure Monitoring (Class I)

• Measure serum creatinine and calculate eGFR 48–96 h after contrast administration – KDIGO protocol. 24

Additional Strategies for High‑Risk Patients

Statin Therapy (Class IIa)

• Short‑term high‑dose statin therapy (e.g., rosuvastatin 40/20 mg, atorvastatin 80 mg, or simvastatin 80 mg) can be considered in high‑risk individuals – ESC recommendation. 19

Hemofiltration (Class IIb)

• Prophylactic hemofiltration (≈ 1000 mL/h fluid replacement) may be used for patients with eGFR < 30 mL/min/1.73 m² undergoing complex procedures; evidence is limited – AHA statement. 21

Hemodialysis (Class III)

• Prophylactic hemodialysis is not recommended – ESC guideline. 19

Interventions Without Benefit (Class III)

• N‑acetylcysteine should not be used for CIN prevention; randomized trials show no reduction in incidence – AHA conclusion. 20
• Furosemide or mannitol are not recommended for prophylaxis – AHA evidence. 20

Key Risk Factors (Class I)

• Pre‑existing renal impairment (eGFR < 60 mL/min/1.73 m²) is the principal risk factor – KDIGO data. 18
• Congestive heart failure (NYHA III/IV) markedly increases risk – AHA findings. 21
• Age > 70 years independently raises CIN risk – AHA analysis. 21
• Higher contrast volumes correlate directly with greater nephropathy risk – AHA evidence. 21

Clinical Outcomes (Observational Evidence)

• In patients with eGFR < 45 mL/min/1.73 m², the adjusted hazard ratio for mortality after contrast exposure is 1.70 compared with those having eGFR 60–75 mL/min/1.73 m² – AHA cohort study. 21

All statements are derived from cited peer‑reviewed sources and reflect the strength of recommendation (Class I = strong, Class IIa/IIb = moderate, Class III = no benefit or harm).

Prevention of Contrast‑Induced Nephropathy – Evidence‑Based Recommendations

1. Identification of High‑Risk Patients

• Patients receiving a total contrast volume greater than 350 mL or >4 mL/kg are at markedly increased risk for CIN; this threshold is derived from European Society of Cardiology (ESC) guidance. 25

2. Mandatory Hydration Protocol (Class I, ESC)

• Standard isotonic saline (0.9 % NaCl) administered at 1.0–1.5 mL/kg/h, beginning 3–12 h before contrast exposure and continued for 6–24 h after the procedure, is the most effective preventive measure and is superior to oral hydration. 25

• Sodium bicarbonate (154 mmol/L in dextrose‑water) given as 3 mL/kg over 1 h before contrast followed by 1 mL/kg/h for 6 h after may be used as an alternative; ESC classifies this as Class IIa (reasonable) or Class III (not indicated) depending on the specific guideline version, reflecting mixed evidence. Saline remains the default choice. 25

3. Contrast Media Selection and Volume Minimization (Class I, ESC)

• Use low‑osmolar or iso‑osmolar contrast agents; high‑osmolar agents should be avoided. In the highest‑risk patients, iso‑osmolar media are preferred. 25

• Limit total contrast volume to <350 mL or <4 mL/kg, and keep the contrast‑volume/eGFR ratio <3.4 to reduce dose‑dependent nephrotoxicity. 25

4. Pharmacologic Adjuncts

4.1 High‑Dose Statin Therapy (Class IIa, Level A, ESC)

• A short‑term, high‑dose statin regimen should be considered for high‑risk patients:

4.2 Furosemide with Matched Hydration (Class IIb, ESC)

• In patients where pre‑procedure hydration cannot be achieved, a protocol combining a 250 mL IV saline bolus (reduced to 150 mL for left‑ventricular dysfunction) with IV furosemide 0.25–0.5 mg/kg, followed by fluid infusion adjusted to match urine output, may be employed. The procedure proceeds once urine output exceeds 300 mL/h, and matched hydration continues for 4 h post‑procedure. This is a Class IIb recommendation for very high‑risk patients. 25

5. Interventions Not Recommended (Class III)

• N‑acetylcysteine should not be used for CIN prevention. The American College of Cardiology (ACC) assigns Class III, Level A evidence, citing the ACT trial (identical CIN incidence of 12.7 % in NAC vs. control) and a meta‑analysis (risk ratio 1.05; 95 % CI 0.73–1.53). 25

• Loop diuretics (including furosemide) and mannitol for prophylaxis are discouraged due to potential harm. 25

• Prophylactic hemodialysis for CKD stage 3 patients is not recommended; hemofiltration may be considered only for stage 4–5 CKD in complex interventions (Class IIb, limited evidence). 25

• Dopamine, calcium‑channel blockers, fenoldopam, atrial natriuretic peptide, and endothelin‑receptor antagonists lack proven efficacy and are not recommended. 25

6. Timing of Subsequent Surgery (Class IIa, Level B, ESC)

• For patients with moderate‑to‑severe CKD who require coronary artery bypass grafting (CABG) after coronary angiography, the surgery should be delayed until renal function has recovered from contrast exposure to avoid compounding acute kidney injury. 25

Prevention of Contrast‑Induced Nephropathy in High‑Risk Adults

Risk Stratification

• Diabetes mellitus combined with pre‑existing renal impairment markedly raises the risk of contrast‑induced nephropathy, with reported CIN rates of 20–50 % in this population. (American Journal of Kidney Diseases, 2007) 26
• A Mehran risk‑score > 16 predicts a 57.3 % probability of CIN and a 21.6 % chance of requiring dialysis. (Kidney International, 2014) 27
• The Mehran score assigns points as follows: hypotension (5), intra‑aortic balloon pump (5), chronic heart failure (5), age > 75 y (4), anemia (3), diabetes (3), serum creatinine > 1.5 mg/dL (4), eGFR 40–60 mL/min/1.73 m² (2), eGFR 20–40 mL/min/1.73 m² (4), eGFR < 20 mL/min/1.73 m² (6), plus 1 point per 100 mL of contrast volume. (Kidney International, 2014) 27

Pre‑Procedure Interventions

Medication Management

• Discontinue nephrotoxic agents—specifically NSAIDs, aminoglycosides, and amphotericin B—at least 24–48 hours before contrast exposure. (American Journal of Kidney Diseases, 2007) 26

Hydration Strategies

• Intravenous isotonic saline (0.9 % NaCl) administered at 1.0–1.5 mL/kg/h, beginning 3–12 hours before contrast and continued for 6–24 hours after the procedure, is a Class I recommendation for CIN prevention. (American Journal of Kidney Diseases, 2013) 28
• Oral hydration alone is insufficient for patients at increased CIN risk; exclusive reliance on oral fluids should be avoided. (Class I) (American Journal of Kidney Diseases, 2013) 28
• Isotonic sodium bicarbonate (154 mEq/L in dextrose‑water) given as 3 mL/kg over 1 hour pre‑contrast followed by 1 mL/kg/h for 6 hours post‑contrast may be used as an alternative to saline, although evidence is mixed. (American Journal of Kidney Diseases, 2007) 26

Contrast Selection & Dose Minimization

• Low‑osmolar or iso‑osmolar contrast media should be used; iso‑osmolar agents (e.g., iodixanol) are associated with a lower incidence of CIN compared with low‑osmolar agents (e.g., iohexol) in patients with renal insufficiency and diabetes. (Class I) (American Journal of Kidney Diseases, 2013) 28
• In patients with eGFR < 30 mL/min/1.73 m², even a single 30 mL dose of contrast can precipitate acute kidney failure. (American Journal of Kidney Diseases, 2007) 26

Common Pitfalls (Evidence‑Based)

• Failure to measure eGFR before contrast administration underestimates renal dysfunction, particularly in elderly individuals or those with reduced muscle mass. (American Journal of Kidney Diseases, 2013) 28
• Neglecting to discontinue nephrotoxic medications (NSAIDs, aminoglycosides) prior to the procedure increases CIN risk. (American Journal of Kidney Diseases, 2007) 26
• Relying solely on oral hydration in high‑risk patients leads to inadequate prophylaxis. (American Journal of Kidney Diseases, 2013) 28

Evidence‑Based Recommendations for Contrast‑Induced Nephropathy (CIN) Prevention and Assessment

Risk Assessment

• Calculate eGFR for all patients at risk – Relying on serum creatinine alone underestimates renal dysfunction, particularly in elderly individuals or those with reduced muscle mass; eGFR provides a more accurate estimate of kidney function. 29

• Mandatory eGFR measurement before contrast exposure – Omitting eGFR assessment before contrast administration leads to missed renal impairment and increases CIN risk, especially in older patients. 29

Medication Management

• Continuing ACE inhibitors, ARBs, and diuretics in stable patients does not raise CIN incidence – Small randomized trials showed no significant increase in CIN when these agents are maintained in patients without acute intercurrent illness. 29

• Discontinue nephrotoxic drugs (e.g., NSAIDs, aminoglycosides) before contrast – Although not directly cited here, this practice is reinforced by the same evidence base that emphasizes medication review to lower CIN risk. 29

Pharmacologic Prophylaxis

• N‑acetylcysteine (NAC) is not recommended for CIN prevention – The American College of Cardiology assigns a Class III, Level A recommendation against NAC, citing the ACT trial (identical 12.7 % CIN incidence with NAC vs. control) and meta‑analysis (risk ratio 1.05; 95 % CI 0.73–1.53). The KDIGO guideline similarly states that NAC provides no benefit for preventing contrast‑induced acute kidney injury. 29

Intravenous Isotonic Sodium Bicarbonate vs. Saline for Contrast‑Induced Nephropathy Prevention

Guideline Recommendations

• KDIGO (2013) recommends intravenous volume expansion with either isotonic sodium chloride or isotonic sodium bicarbonate (154 mEq/L) for patients at increased risk of contrast‑induced acute kidney injury, rather than no IV volume expansion (Class 1A). 30

• The American Society of Nephrology (based on the 2013 KDIGO guideline) states that oral hydration alone is insufficient for high‑risk patients; intravenous hydration is mandatory. 30

Primary Hydration Strategy

• Default regimen: administer isotonic saline at 1.0–1.5 mL/kg/hour beginning 3–12 hours before contrast exposure and continuing 6–24 hours after contrast for all patients with elevated CIN risk. (Class I recommendation).** 30

• Rationale: Saline is readily available, avoids preparation errors, and recent high‑quality evidence shows it is at least as effective as bicarbonate for preventing CIN.** 30

Specific Sodium Bicarbonate Protocol (when chosen)

• Pre‑procedure bolus: give isotonic sodium bicarbonate (154 mEq/L in dextrose‑water) at 3 mL/kg over 1 hour before contrast administration.** 30

• Post‑procedure infusion: continue isotonic sodium bicarbonate at 1 mL/kg/hour for 6 hours after the procedure.** 30

• Strength of recommendation: Considered a reasonable alternative (Class IIa) in settings where rapid pre‑procedure hydration is needed (e.g., emergency procedures).** 30

Adjunctive Measures (independent of hydration choice)

• Use low‑osmolar or iso‑osmolar contrast media (Class I). 30

• Limit contrast volume to ≤350 mL or ≤4 mL/kg, maintaining a contrast‑volume/eGFR ratio <3.4.** 30

• Discontinue nephrotoxic drugs (e.g., NSAIDs, aminoglycosides) 24–48 hours before contrast exposure.** 30

• Avoid N‑acetylcysteine as a substitute for IV hydration (Class III, Level A).** 30

Clinical Decision Algorithm

• When to prefer saline (default): any elective procedure where adequate pre‑procedure hydration time is available.** 30

• When bicarbonate may be considered:

  • Emergency procedures with limited time for pre‑hydration (benefit observed in subgroup analyses, OR ≈ 0.16).** 30
  • Settings where a rapid 3 mL/kg pre‑procedure bolus can be safely delivered.** 30

• When to avoid bicarbonate:

  • Elective procedures where saline hydration can be optimized.** 30
  • Intensive care settings with complex acid‑base disorders or high risk of volume overload.** 30

Bottom Line

• Isotonic saline remains the evidence‑based default for CIN prevention; sodium bicarbonate is a reasonable alternative primarily in emergency contexts where a rapid bolus protocol is feasible. Recent high‑quality data show no superiority of bicarbonate over saline, and practical considerations (availability, compounding safety) favor saline in most clinical scenarios. 30

N‑Acetylcysteine Is Not Effective for Preventing Contrast‑Induced Nephropathy

Evidence Against NAC Use

• The KDIGO 2020 conference statement concludes that N‑acetylcysteine provides no benefit for preventing contrast‑induced acute kidney injury, supporting a Class III, Level A recommendation against its use. 31
• The 2013 KDOQI guideline notes that early meta‑analyses of NAC trials were heterogeneous and yielded conflicting results, highlighting methodological limitations that undermine any perceived benefit. 32

Recommended Preventive Measures (Supported by the Same Evidence Base)

• Intravenous isotonic saline (0.9 % NaCl) administered at 1.0–1.5 mL kg⁻¹ h⁻¹, beginning 3–12 hours before contrast exposure and continued for 6–24 hours afterward, is the only intervention consistently shown to lower the risk of contrast‑induced nephropathy. 32
• Oral N‑acetylcysteine should not be used as a substitute for intravenous isotonic crystalloid hydration in high‑risk patients, as it does not confer renal protection. 32
• Intravenous N‑acetylcysteine should be avoided because it is associated with potentially serious adverse effects (e.g., hypertension, tachycardia) and has no demonstrated efficacy in preventing contrast‑induced kidney injury. 32

Management of Repeat Contrast Imaging in Patients with Moderate Chronic Kidney Disease

Risk Assessment

• Patients with a baseline serum creatinine of 164 µmol/L (≈1.85 mg/dL) have an estimated GFR of roughly 30–45 mL/min/1.73 m², placing them in the moderate CKD range and increasing their risk for contrast‑induced nephropathy (CIN) when contrast is repeated within 48 hours【33】【34】.
• Pre‑existing renal impairment (eGFR < 60 mL/min/1.73 m²) is the principal risk factor for developing CIN【33】.

Hydration Protocol (Preventive Measure)

• Intravenous isotonic saline (0.9 % NaCl) is the most effective prophylaxis for CIN and should be administered as the cornerstone of prevention【33】【34】.
• Dosage: 0.9 % NaCl at 1.0–1.5 mL/kg/h, initiated as soon as possible (ideally 3–12 hours before contrast, but immediately if the window is short) and continued for 6–24 hours after contrast exposure【33】【34】.
• Oral hydration alone is insufficient and is explicitly contraindicated in high‑risk patients (Class I recommendation)【34】.

Contrast Media Selection and Volume Minimization

• Use only low‑osmolar or iso‑osmolar contrast agents (Class I recommendation); high‑osmolar agents are contraindicated【33】【34】.
• Coordinate with the radiologist to employ the absolute minimum volume required for diagnostic quality【33】.

Medication Management

Nephrotoxic Drug Discontinuation

• Stop nephrotoxic medications (e.g., NSAIDs, aminoglycosides) at least 24–48 hours before the contrast study when clinically feasible【34】.

Metformin

• Withhold metformin at the time of contrast administration and for 48 hours afterward; resume only after confirming stable or improving renal function【34】.

Prophylaxis Contraindications

• Prophylactic hemodialysis is not recommended for CIN prevention (Class III, Level A)【33】.

Imaging Decision‑Making

• If the clinical question can be answered with non‑contrast modalities (e.g., ultrasound or non‑contrast MRI), these should be considered to avoid additional contrast exposure【33】【35】.
• Ultrasound contrast agents are not nephrotoxic and may be appropriate for certain vascular imaging needs【35】.
• Do not delay a clinically indicated scan; with appropriate prophylaxis, the diagnostic benefit generally outweighs the CIN risk【35】.